

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 25766

Title: Treatment of chronic hepatitis C with direct-acting antivirals: the role of resistance

Reviewer's code: 00004603

Reviewer's country: United States

Science editor: Ya-Juan Ma

Date sent for review: 2016-03-22 17:26

Date reviewed: 2016-04-02 06:02

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The problem of resistance to DAA treatment of hepatitis C is very significant. Since DAA is such promising, but expensive way of HCV-infection treatment, it is very important to know the limitations that patients can face. This is an excellent paper that overviews the reasons for resistance to DAA treatment. I have no problem with this manuscript, it is well and clearly written and provides the detailed information on possible negative outcomes of DAA treatment in HCV patients.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 25766

Title: Treatment of chronic hepatitis C with direct-acting antivirals: the role of resistance

Reviewer's code: 00068235

Reviewer's country: Pakistan

Science editor: Ya-Juan Ma

Date sent for review: 2016-03-22 17:26

Date reviewed: 2016-04-11 12:53

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The article entitled "Treatment of chronic hepatitis C with direct acting antivirals: the role of resistance" Jimenez-Perez et al., is well written and well presented, whoever I have few concerns 1. Where the author describes the genome of virus, also describe the role of 5'UTR and 3'UTR. 2. What is the probability of occurrence of single site mutant and double site mutant? If we use single drug, what is the chances of occurrence of mutant against that drug and when we use combination of drugs acting on 2 different targets like polymerase and protease, what is the chances of occurrence of double site mutant? Already published, please include in your paper. 3. If you find papers, add the real life experience of Sofosbuvir + Daclatasvir and Sofosbuvir + Ledipasvir treatment failures / mutation rates. The paper is accepted for publication in World Journal of Gastroenterology after minor revision.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 25766

Title: Treatment of chronic hepatitis C with direct-acting antivirals: the role of resistance

Reviewer's code: 00012216

Reviewer's country: Spain

Science editor: Ya-Juan Ma

Date sent for review: 2016-03-22 17:26

Date reviewed: 2016-04-12 22:43

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Jiménez-Perez et al carry out a well-structured, interesting and easy to read review about the role of HCV resistant variants to direct acting antivirals (DAA). I would only add a minor suggestion in the paragraph about host-dependent factors, where I would add some comments on the role of specific cytotoxic T cell restoration after DAA as a potential mechanism involved in complete HCV clearing (J Hepatol 2014; 61: 538-543, World J Gastroenterol 2015; 21(12): 3480-3491).